Audited August 3, 2026
All four claims describe reconstitution volume, unit conversion, and dosing protocols for IGF-1 LR3 that lack peer-reviewed clinical trial support, published protocols, or ClinicalTrials.gov registration. While BAC water is a standard peptide solvent and dose titration is a recognized practice pattern in research communities, these specific numeric prescriptions (1 mL, 10 units = 100 mcg, 4-unit start, 5–8 unit maintenance) are not documented in published human safety or efficacy data for IGF-1 LR3. Reconstitution volume and syringe concentration are user-determined arithmetic, not fixed pharmacological parameters—PeptIQ's own educational materials confirm this principle.
Share this audit
One link — full verdict, every claim, and PubMed citations included.
Shareable link includes the full verdict, claims, and PubMed citations.
Post captionshow
igf1lr3 shud reconstitute with 1ml bac water. so every 10 units is 100mcg. first week you start at 4 units (40mcg) then 50-80 (5-8 units)
Claim breakdown
4 claims“igf1lr3 should be reconstituted with 1ml BAC water.”
No peer-reviewed literature, clinical trials, or published protocols found specifying 1 mL BAC water as the reconstitution volume for IGF-1 LR3. Reconstitution volume is dose-dependent arithmetic (mass ÷ desired concentration), not a fixed protocol—PeptIQ's own FAQ confirms this principle applies universally across peptides.
“Every 10 units of reconstituted igf1lr3 is 100mcg.”
No peer-reviewed literature or clinical trial data found establishing a fixed conversion ratio of 10 units = 100 mcg for IGF-1 LR3. Syringe unit concentration is determined by reconstitution volume chosen by the user, not by the peptide itself—this is arithmetic, not a pharmacological property.
“The starting dose for igf1lr3 is 4 units (40mcg).”
No registered human clinical trials, peer-reviewed protocols, or published dosing guidelines found for IGF-1 LR3 specifying 4 units (40 mcg) as a starting dose. IGF-1 LR3 human safety and efficacy data in the published literature remains extremely limited.
“Subsequent doses for igf1lr3 range from 50-80mcg (5-8 units).”
No registered human clinical trials, peer-reviewed dosing protocols, or published guidelines found specifying 50–80 mcg (5–8 units) as maintenance doses for IGF-1 LR3. Human dose-response and safety data for this compound are not available in the clinical trial or peer-reviewed literature.
This audit is for educational purposes only. Not medical advice. Science evolves — always check citation dates and consult a qualified professional.
Report an error